Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
IPO Year:
Exchange: NASDAQ
Website: grifols.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2024 | Hold → Sell | Deutsche Bank | |
| 4/12/2023 | Equal-Weight → Overweight | Morgan Stanley | |
| 3/3/2023 | Overweight → Equal-Weight | Morgan Stanley | |
| 2/16/2023 | Underweight → Equal Weight | Barclays | |
| 1/18/2023 | Hold → Buy | Jefferies | |
| 4/8/2022 | Equal-Weight | Morgan Stanley | |
| 11/5/2021 | Buy → Hold | Deutsche Bank | |
| 10/19/2021 | Overweight → Underweight | Barclays | |
| 10/6/2021 | Neutral → Buy | Citigroup |
SC 13G/A - Grifols SA (0001438569) (Subject)
SC 13G/A - Grifols SA (0001438569) (Subject)
SC 13G - Grifols SA (0001438569) (Subject)
BARCELONA, Spain, Jan. 4, 2022 /PRNewswire/ -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today announced the acquisition of its first donation center in Canada as part of the company's commitment to increase the availability of lifesaving plasma medicines in the country. In a share-purchase agreement, Grifols Canada Therapeutics Inc has acquired Prometic Plasma Resources Inc's (PPR) donation center in Winnipeg from Kedrion for USD 4 million in cash. With the center, Grifols furthers
‘Chronos-PD' is looking for biological signals that could indicate increased chance of developing Parkinson's disease (PD) years before symptoms appear, leading to new diagnostic tools and disease-modifying therapiesPart of broad Grifols program to find disease-revealing clues in more than 100 million proprietary plasma samples connected to real-world data on thousands of disease states in many therapeutic areasCutting-edge use of AI and proteomics technology paired with real-world evidence underscores the company's ongoing commitment to bold scientific innovation to benefit patients BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ:GRFS), a global
Urges Improved Disclosure Around Key Issues for the Benefit of Grifols Shareholders Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.5% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Spanish National Securities Market Commission (the "CNMV") calling the CNMV's attention to the troubling and value destructive lack of transparency by Grifols and its Board of Directors (the "Board"). In the letter, Mason urges the CNMV to consider the benefits to all Grifols shareholders from improved disclosure around several key issues, including: Related-party transac
Urges Board to Prove its Independence by Accepting Tomas Daga's Voluntary Resignation Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board") requesting the disclosure of important information regarding Tomas Daga, a nearly 25-year member of the Board and the Grifols family's closest advisor, so that Grifols shareholders have a better understanding of his relationship to Grifols and can make an informed decision about the suitability of his continued service on the Board.
SAN CARLOS, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint-resistant cancers, and a subsidiary of Grifols, announced today that the first patient has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of the first recombinant polyclonal drug candidate, GIGA-2339, for the treatment of hepatitis B virus (HBV) infection. "The initiation of this Phase 1 trial with GIGA-2339 represents a milestone in our mission to develop the next generation of antibody drugs for addressing infectious disease treatment," said Carter Keller, senior vice
Believes Substantially Greater Value Than Any Brookfield Bid Can Be Realized by Ousting Conflicted Directors and Restoring Majority Control of Independent Shareholders Demands Rightful Addition of Paul Herendeen to the Board via Voluntary Appointment or Shareholder Vote Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board"). In the letter, Mason reiterated the Company's corporate governance deficiencies, which have inflicted large losses on all shareholders and resulted
Sends Letter to Board Detailing Board's Conflicts of Interest and History of Poor Capital Allocation Expresses Urgent Need for Independent Directors and Proper Oversight to Unlock Value Believes Rumored Brookfield Transaction Substantially Undervalues Grifols Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board"). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107873955/en/Historical Forward EV/EBITDA Multip
Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasisGrifols surgical bleeding management treatments form part of an increasingly robust portfolio of innovative therapeutics enhancing the health and well-being of patients BARCELONA, Spain, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced that its plasma-protein based fibrin sealant (FS) for controlling surgical bleeding has received approval from the United States Food and Drug Administration (FDA) for p
Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure to sulfur mustard, a chemical warfare agent A successful preclinical study of this potentially innovative therapeutic could lead to an FDA license for one of the first medical treatments for sulfur mustard ocular injury Grifols also plans to start a phase 2 clinical trial of an OSIG for dry eye disease in the first half of 2025, part of the company's broadening innovation pipeline to enhance the lives of patients BARCELONA, Spain, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Grifols ((MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare co
The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs GigaGen's recombinant polyclonals are part of Grifols' robust innovation strategy and commitment to delivering the next generation of antibody drugs for patients and healthcare professionals SAN CARLOS, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint-resistant cancers, and a subsidiary of Grifols, announced today that it has been awarded a contract by the Biomedical Adva
GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic hepatitis B virus (HBV) infection; trial initiation expected in Q4 2024 Containing more than 1,000 fully human recombinant anti-HBV antibodies, GIGA-2339 reproduces the human body's natural immune response GigaGen's recombinant polyclonals are part of Grifols' robust innovation strategy and commitment to delivering the next generation of antibody drugs for patients and healthcare professionals SAN CARLOS, Calif. , July 31, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infec
Deutsche Bank downgraded Grifols, S.A. from Hold to Sell
Morgan Stanley upgraded Grifols, S.A. from Equal-Weight to Overweight
Morgan Stanley downgraded Grifols, S.A. from Overweight to Equal-Weight
Barclays upgraded Grifols, S.A. from Underweight to Equal Weight
Jefferies upgraded Grifols, S.A. from Hold to Buy
Morgan Stanley initiated coverage of Grifols, S.A. with a rating of Equal-Weight
Deutsche Bank downgraded Grifols from Buy to Hold
Barclays downgraded Grifols, S.A. from Overweight to Underweight
Citigroup upgraded Grifols, S.A. from Neutral to Buy
Deutsche Bank upgraded Grifols, S.A. from Hold to Buy
Sends Letter to Board Detailing Board's Conflicts of Interest and History of Poor Capital Allocation Expresses Urgent Need for Independent Directors and Proper Oversight to Unlock Value Believes Rumored Brookfield Transaction Substantially Undervalues Grifols Mason Capital Management LLC ("Mason"), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. ("Grifols" or the "Company") (BME: GRF) (NASDAQ:GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the "Board"). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107873955/en/Historical Forward EV/EBITDA Multip
BARCELONA, Spain, April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC"). Grifols' annual report under Form 20-F is a critical component of the company's commitment to transparency and accountability. The filing of the annual report provides investors with an overview of the company's governance practices, including informa
Victor Grifols Roura, who devoted 50 years to building Grifols in senior roles including CEO for 30 years, retires as non-executive Chairperson and is designated as Chairperson of Honor in recognition of his numerous contributionsSteven F. Mayer, former Co-Head of Global Private Equity and Chairman of the Investment Committee of private investment firm Cerberus Capital Management, L.P., with more than 10 years serving as a Grifols independent board member, is appointed as Executive ChairpersonChanges further evidence of the Board of Directors' focus on strategic objectives, operational excellence, and deleveraging balance sheetBARCELONA, Spain, Oct. 3, 2022 /PRNewswire/ -- Grifols (MCE: GRF)
SAN CARLOS, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Alkahest, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced the appointment of Dr. César Cerezo M.D., Ph.D., as chief medical officer. He will be responsible for leading and providing strategic direction to the clinical development and medical teams. "Dr. Cerezo brings to Alkahest robust and broad experience both as a practicing and research physician, and as an experienced pharmaceutical and biotechnology industry leader. Having played a significant role in the advancement of multiple clinical developmen
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)
6-K - Grifols SA (0001438569) (Filer)